Anteo Diagnostics: ASX Spotlight Series (March 2015)

Company Presentations

by Carolyn Herbert

Anteo Diagnostics Limited (ASX:ADO) CEO Dr Geoff Cumming presents at ASX Spotlight Series in New York. 
The lifesciences company’s presentation includes a company profile, financial snapshot, core competencies and IP strategy.  
Dr Cumming also discusses Anteo’s products, diagnostic industry drivers, blue sky opportunities and planned milestones for 2015. 
Introducing the company Dr Cumming says, “I would like to give you a brief overview of Anteo Diagnostics, what we do, the composition of the company, our technology, some of the areas we are involved in and why we believe that we are a rapidly growing company that will accelerate that growth into future, and why it might represent a worthwhile investment opportunity for you. 
We work in the biotechnology space. Australia does have a vibrant healthcare, lifesciences biotechnology space.”

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.